Filed with ASX · · 4 pages · English
The trial continues to progress, with a high percentage of patients opting to participate in the Open Label Extension study, which will provide additional long-term safety and efficacy data. This achievement reduces execution risk associated with long-duration trial retention and treatment adherence, crucial for the study's success.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. Dimerix HQ 425 Smith St, Fitzroy 3065 Victoria, Australia T. 1300 813 321 E. info@dimerix.com For Immediate Release DMX-200 ACTION3 PHASE 3 TRIAL: FIRST 100 PATIENTS COMPLETE DOUBLE-BLIND...
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix